Physician profile
Michael Jay Fields
NPI 1154433688
$7,394.82
in general payments reported to CMS, 2019-2025
24 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Pediatric Pulmonology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,081 · 2020: $460 · 2021: $279 · 2022: $410 · 2023: $4,866 · 2024: $71.06 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,635 · Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,635.00 |
| Food and Beverage | $529.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,660.02 | 2019-2023 | Ofev |
| Intuitive Surgical, INC. | $683.74 | 2019 | |
| Chiesi USA, INC. | $495.41 | 2019-2022 | |
| Abbvie INC. | $236.65 | 2019-2022 | |
| Philips North America LLC | $191.80 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $133.05 | 2022-2023 | |
| Advanced Respiratory, INC | $121.62 | 2020-2021 | |
| Baxter Healthcare | $120.74 | 2022-2025 | Hillrom - Synclara Cough System, Hillrom - Volara System, Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $108.53 | 2023 | Dupixent |
| Alcresta Therapeutics, INC. | $93.21 | 2025 | Relizorb |
| Aimmune Therapeutics, INC. | $89.90 | 2024-2025 | Zenpep |
| Abbott Laboratories | $83.55 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $61.45 | 2020-2023 | Trikafta |
| Astrazeneca Pharmaceuticals Lp | $59.37 | 2021-2025 | Fasenra |
| Laborie Medical Technologies Corp. | $44.78 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $44.06 | 2023-2024 | Tobi Podhaler |
| Allergan, INC. | $34.36 | 2019 | |
| Genzyme Corporation | $29.31 | 2019 | |
| Amgen INC. | $23.34 | 2022 | |
| Electromed, INC. | $19.64 | 2019 | |
| Vapotherm INC | $16.58 | 2022 | |
| Gilead Sciences, INC. | $15.80 | 2022 | |
| Aytu Biopharma, INC. | $14.70 | 2020 | |
| Glaxosmithkline, LLC. | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.